

Publications, Cecilie Hveding Blimark

- 1) Melphalan mg/m² with stem cell support as first relapse treatment is safe and 100 effective for myeloma patients with long remission after autologous stem cell transplantation. Blimark C, Veskovski L, Westin J, Rödger S, Brune M, Hjorth M, Holmberg E, Andersson PO, Mellqvist UH. *Eur J Haematol.* 2011 Aug;87(2):117-22.
- 2) Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. *Blood.* 2010 Oct 14;116(15):2651-5.
- 3) Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. *Blood.* 2010 Jun 17;115(24):4991-8.
- 4) Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Kristinsson SY, Björkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. *Haematologica.* 2009 Dec;94(12):1714-20.
- 5) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Kristinsson SY, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. *Int J Cancer.* 2009 Nov 1;125(9):2147-50.
- 6) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, Wahlin A, Björkholm M, Turesson I. *Blood.* 2009 Jul 23;114(4):791-5.
- 7) Percutaneous vertebroplasty at C2: case report of a patient with multiple myeloma and a literature review. Rodriguez-Catarino M, Blimark C, Willén J, Mellqvist UH, Rödger S. *Eur Spine J.* 2007 Dec;16 Suppl 3:242-9.
- 8) Brief report : Monoclonal gammopathy of undetermined significance and risk of infections: A population-based study Sigurdur Y Kristinsson MD, PhD, Min Tang PhD, Ruth M Pfeiffer PhD, Magnus Björkholm MD, PhD, Lynn R Goldin PhD, Cecilie Blimark MD,

Ulf-Henrik Mellqvist MD, PhD, Anders Wahlin MD, PhD, Ingemar Turesson MD, PhD, Ola Landgren MD, PhD; *Haematologica*. 2011 Dec 16.

- 9) Immune-Related conditions and risk of multiple myeloma and Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study. Ebba Lindqvist, Lynn R Goldin, Ola Landgren, Cecilie Blimark, Ulf-Henrik Mellqvist, Ingemar Turesson, Anders Wahlin, Magnus Björkholm, Sigurdur Y Kristinsson
Blood. 2011 Dec 8;118(24):6284-91.
- 10) Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Liwing J¹, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, Enestig J, Flogegård M, Forsberg K, Gruber A, Haglöf K, Kwiele H, Johansson P, Lauri B, Mellqvist UH, Swedin A, Svensson M, Näsman P, Alici E, Gahrton G, Aschan J, Nahi H
Br J Haematol. 2014 Mar;164(5):684-93.
- 11) Treatment for high-risk smoldering myeloma.
Kristinsson SY, Holmberg E, Blimark C.
N Engl J Med. 2013 Oct 31;369(18):1762-3.
- 12) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. *Blood*. 2013 Jun 6;121(23):4647-54.
- 13) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.
Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, Wahlin A, Björkholm M, Kristinsson SY. *Blood*. 2011 Dec 8;118(24):6284-91.
- 14) Multiple Myeloma and Infections: A Population-Based Study on 9,253 Multiple Myeloma Patients
Cecilie Blimark, Erik Holmberg, Ulf-Henrik Mellqvist, Ola Landgren, Magnus Björkholm, Malin L Hulcrantz, Christian Kjellander, Ingemar Turesson and Sigurdur Y. Kristinsson. *Haematologica* 2015 Jan; 100(1):107-13
- 15) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A,

Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwala N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators.
N Engl J Med. 2015 Jan 8;372(2):142-52.

- 16) Survival in multiple myeloma patients who develop second malignancies:
a population-based cohort study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Wahlin A, Mailankody S, Blimark C, Hultcrantz M, Porwit A, Landgren O, Kristinsson SY.
Haematologica. 2015 Dec 17

- 17) Secondary immunodeficiency in lymphoproliferative malignancies.

Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F.
Hematol Oncol. 2016 Sep;34(3):121-32. doi: 10.1002/hon.2323. Review

- 18) Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlovski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators..
N Engl J Med. 2016 Oct 6;375(14):1319-1331

- 19) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group..
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282